Table of Contents Author Guidelines Submit a Manuscript
Journal of Diabetes Research
Volume 2015, Article ID 680867, 8 pages
http://dx.doi.org/10.1155/2015/680867
Research Article

Changes in Plasma Levels of N-Arachidonoyl Ethanolamine and N-Palmitoylethanolamine following Bariatric Surgery in Morbidly Obese Females with Impaired Glucose Homeostasis

1Diabetes Research Group, Institute of Life Sciences, Swansea University, Swansea SA2 8PP, UK
2Department of Diabetes & Endocrinology, Morriston Hospital, ABM University Health Board, Swansea SA6 6NL, UK
3Welsh Institute of Metabolic and Obesity Surgery, Morriston Hospital, ABM University Health Board, Swansea SA6 6NL, UK
4Division of Medical Sciences and Graduate Entry Medicine, University of Nottingham, Royal Derby Hospital, Derby DE22 3DT, UK
5Centre for Analytical Bioscience, School of Pharmacy, University of Nottingham, Nottingham NG7 2RD, UK

Received 1 December 2014; Revised 11 March 2015; Accepted 12 March 2015

Academic Editor: Carlos Martinez Salgado

Copyright © 2015 Akhila Mallipedhi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. B. Horvth, P. Mukhopadhyay, G. Hask, and P. Pacher, “The endocannabinoid system and plant-derived cannabinoids in diabetes and diabetic complications,” The American Journal of Pathology, vol. 180, no. 2, pp. 432–442, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. J. C. Cable, G. D. Tan, S. P. Alexander, and S. E. O'Sullivan, “The effects of obesity, diabetes and metabolic syndrome on the hydrolytic enzymes of the endocannabinoid system in animal and human adipocytes,” Lipids in Health and Disease, vol. 13, no. 1, article 43, 2014. View at Publisher · View at Google Scholar · View at Scopus
  3. P. Pacher, S. Bátkai, and G. Kunos, “The endocannabinoid system as an emerging target of pharmacotherapy,” Pharmacological Reviews, vol. 58, no. 3, pp. 389–462, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. V. di Marzo, A. Fontana, H. Cadas et al., “Formation and inactivation of endogenous cannabinoid anandamide in central neurons,” Nature, vol. 372, no. 6507, pp. 686–691, 1994. View at Publisher · View at Google Scholar · View at Scopus
  5. V. Di Marzo and D. G. Deutsch, “Biochemistry of the endogenous ligands of cannabinoid receptors,” Neurobiology of Disease, vol. 5, no. 6, pp. 386–404, 1998. View at Publisher · View at Google Scholar · View at Scopus
  6. V. Di Marzo, T. Bisogno, L. de Petrocellis, D. Melck, and B. R. Martin, “Cannabimimetic fatty acid derivatives: the anandamide family and other 'endocannabinoids',” Current Medicinal Chemistry, vol. 6, no. 8, pp. 721–744, 1999. View at Google Scholar · View at Scopus
  7. J. M. Walker, J. F. Krey, C. J. Chu, and S. M. Huang, “Endocannabinoids and related fatty acid derivatives in pain modulation,” Chemistry and Physics of Lipids, vol. 121, no. 1-2, pp. 159–172, 2002. View at Publisher · View at Google Scholar · View at Scopus
  8. M. F. Bennetzen, “Investigations of the endocannabinoid system in adipose tissue: effects of obesity/weight loss and treatment options,” Danish Medical Bulletin, vol. 58, no. 4, Article ID B4269, 2011. View at Google Scholar · View at Scopus
  9. M.-P. Gonthier, L. Hoareau, F. Festy et al., “Identification of endocannabinoids and related compounds in human fat cells,” Obesity, vol. 15, no. 4, pp. 837–845, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. I. Matias, M.-P. Gonthier, P. Orlando et al., “Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia,” Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 8, pp. 3171–3180, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. S. Engeli, J. Böhnke, M. Feldpausch et al., “Activation of the peripheral endocannabinoid system in human obesity,” Diabetes, vol. 54, no. 10, pp. 2838–2843, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Côté, I. Matias, I. Lemieux et al., “Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men,” International Journal of Obesity, vol. 31, no. 4, pp. 692–699, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Blüher, S. Engeli, N. Klöting et al., “Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity,” Diabetes, vol. 55, no. 11, pp. 3053–3060, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. J. Abdulnour, S. Yasari, R. Rabasa-Lhoret et al., “Circulating endocannabinoids in insulin sensitive vs. Insulin resistant obese postmenopausal women. A MONET group study,” Obesity (Silver Spring), vol. 22, no. 1, pp. 211–216, 2014. View at Publisher · View at Google Scholar · View at Scopus
  15. F. Fernández-Aranda, S. Sauchelli, A. Pastor et al., “Moderate-vigorous physical activity across body mass index in females: moderating effect of endocannabinoids and temperament,” PLoS ONE, vol. 9, no. 8, Article ID e104534, 2014. View at Publisher · View at Google Scholar
  16. V. Di Marzo, A. Verrijken, A. Hakkarainen et al., “Role of insulin as a negative regulator of plasma endocannabinoid levels in obese and nonobese subjects,” European Journal of Endocrinology, vol. 161, no. 5, pp. 715–722, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. V. Di Marzo, “The endocannabinoid system in obesity and type 2 diabetes,” Diabetologia, vol. 51, no. 8, pp. 1356–1367, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. G. Kunos and J. Tam, “The case for peripheral CB1 receptor blockade in the treatment of visceral obesity and its cardiometabolic complications,” British Journal of Pharmacology, vol. 163, no. 7, pp. 1423–1431, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. T. M. D'Eon, K. A. Pierce, J. J. Roix, A. Tyler, H. Chen, and S. R. Teixeira, “The role of adipocyte insulin resistance in the pathogenesis of obesity-related elevations in endocannabinoids,” Diabetes, vol. 57, no. 5, pp. 1262–1268, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. J. C. Cable, G. D. Tan, S. P. Alexander, and S. E. O'Sullivan, “The activity of the endocannabinoid metabolising enzyme fatty acid amide hydrolase in subcutaneous adipocytes correlates with BMI in metabolically healthy humans,” Lipids in Health and Disease, vol. 10, article 129, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. D. Cota, G. Marsicano, M. Tschöp et al., “The endogenous cennabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis,” Journal of Clinical Investigation, vol. 112, no. 3, pp. 423–431, 2003. View at Publisher · View at Google Scholar · View at Scopus
  22. J. C. Sipe, T. M. Scott, S. Murray et al., “Biomarkers of endocannabinoid system activation in severe obesity,” PLoS ONE, vol. 5, no. 1, Article ID e8792, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. C. R. Trillou, M. Arnone, C. Delgorge et al., “Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice,” The American Journal of Physiology—Regulatory Integrative and Comparative Physiology, vol. 284, no. 2, pp. R345–R353, 2003. View at Publisher · View at Google Scholar · View at Scopus
  24. V. K. Vemuri, D. R. Janero, and A. Makriyannis, “Pharmacotherapeutic targeting of the endocannabinoid signaling system: drugs for obesity and the metabolic syndrome,” Physiology and Behavior, vol. 93, no. 4-5, pp. 671–686, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. H. Buchwald, Y. Avidor, E. Braunwald et al., “Bariatric surgery: a systematic review and meta-analysis,” Journal of the American Medical Association, vol. 292, no. 14, pp. 1724–1737, 2004. View at Publisher · View at Google Scholar · View at Scopus
  26. S. Engeli, K. Heusser, J. Janke et al., “Peripheral endocannabinoid system activity in patients treated with sibutramine,” Obesity, vol. 16, no. 5, pp. 1135–1137, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. V. Di Marzo, M. Côté, I. Matias et al., “Changes in plasma endocannabinoid levels in viscerally obese men following a 1 year lifestyle modification programme and waist circumference reduction: Associations with changes in metabolic risk factors,” Diabetologia, vol. 52, no. 2, pp. 213–217, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. A. Guijarro, D. Osei-Hyiaman, J. Harvey-White et al., “Sustained weight loss after Roux-en-Y gastric bypass is characterized by down regulation of endocannabinoids and mitochondrial function,” Annals of Surgery, vol. 247, no. 5, pp. 779–790, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. A. Quercioli, F. Montecucco, Z. Pataky et al., “Improvement in coronary circulatory function in morbidly obese individuals after gastric bypass-induced weight loss: relation to alterations in endocannabinoids and adipocytokines,” European Heart Journal, vol. 34, no. 27, pp. 2063–2073, 2013. View at Publisher · View at Google Scholar · View at Scopus
  30. G. Domínguez-Vega, M. Pera, J. M. Ramón et al., “A comparison of laparoscopic versus open repair for the surgical treatment of perforated peptic ulcers,” Cirugia Espanola, vol. 91, no. 6, pp. 372–377, 2013. View at Publisher · View at Google Scholar · View at Scopus
  31. N. Scopinaro, E. Gianetta, D. Civalleri, U. Bonalumi, and V. Bachi, “Bilio-pancreatic bypass for obesity: 1. An experimental study in dogs,” British Journal of Surgery, vol. 66, no. 9, pp. 613–617, 1979. View at Publisher · View at Google Scholar · View at Scopus
  32. J. C. Levy, D. R. Matthews, and M. P. Hermans, “Correct homeostasis model assessment (HOMA) evaluation uses the computer program,” Diabetes Care, vol. 21, no. 12, pp. 2191–2192, 1998. View at Google Scholar · View at Scopus
  33. G. I. Uwaifo, E. M. Fallon, J. Chin, J. Elberg, S. J. Parikh, and J. A. Yanovski, “Indices of insulin action, disposal, and secretion derived from fasting samples and clamps in normal glucose-tolerant black and white children,” Diabetes Care, vol. 25, no. 11, pp. 2081–2087, 2002. View at Publisher · View at Google Scholar · View at Scopus
  34. K. N. Bojsen-Møller, C. Dirksen, N. B. Jørgensen et al., “Increased hepatic insulin clearance after Roux-en-Y gastric bypass,” The Journal of Clinical Endocrinology and Metabolism, vol. 98, no. 6, pp. E1066–E1071, 2013. View at Publisher · View at Google Scholar
  35. D. Richardson, C. A. Ortori, V. Chapman, D. A. Kendall, and D. A. Barrett, “Quantitative profiling of endocannabinoids and related compounds in rat brain using liquid chromatography-tandem electrospray ionization mass spectrometry,” Analytical Biochemistry, vol. 360, no. 2, pp. 216–226, 2007. View at Publisher · View at Google Scholar · View at Scopus
  36. D. Benaiges, J. A. Flores Le-Roux, J. Pedro-Botet et al., “Sleeve gastrectomy and Roux-en-Y gastric bypass are equally effective in correcting insulin resistance,” International Journal of Surgery, vol. 11, no. 4, pp. 309–313, 2013. View at Publisher · View at Google Scholar · View at Scopus
  37. F. Leonetti, D. Capoccia, F. Coccia et al., “Obesity, type 2 diabetes mellitus, and other comorbidities: a prospective cohort study of laparoscopic sleeve gastrectomy vs medical treatment,” Archives of Surgery, vol. 147, no. 8, pp. 694–700, 2012. View at Publisher · View at Google Scholar · View at Scopus
  38. A. Jiménez, R. Casamitjana, L. Flores et al., “Long-term effects of sleeve gastrectomy and roux-en-y gastric bypass surgery on type 2 diabetes mellitus in morbidly obese subjects,” Annals of Surgery, vol. 256, no. 6, pp. 1023–1029, 2012. View at Publisher · View at Google Scholar · View at Scopus
  39. R. M. Craft, J. A. Marusich, and J. L. Wiley, “Sex differences in cannabinoid pharmacology: a reflection of differences in the endocannabinoid system?” Life Sciences, vol. 92, no. 8-9, pp. 476–481, 2013. View at Publisher · View at Google Scholar · View at Scopus
  40. T. Karasu, T. H. Marczylo, M. Maccarrone, and J. C. Konje, “The role of sex steroid hormones, cytokines and the endocannabinoid system in female fertility,” Human Reproduction Update, vol. 17, no. 3, Article ID dmq058, pp. 347–361, 2011. View at Google Scholar · View at Scopus
  41. D. G. Carey, A. B. Jenkins, L. V. Campbell, J. Freund, and D. J. Chisholm, “Abdominal fat and insulin resistance in normal and overweight women: direct measurements reveal a strong relationship in subjects at both low and high risk of NIDDM,” Diabetes, vol. 45, no. 5, pp. 633–638, 1996. View at Publisher · View at Google Scholar · View at Scopus
  42. I. Matias, M.-P. Gonthier, S. Petrosino et al., “Role and regulation of acylethanolamides in energy balance: focus on adipocytes and β-cells,” British Journal of Pharmacology, vol. 152, no. 5, pp. 676–690, 2007. View at Publisher · View at Google Scholar · View at Scopus
  43. S. Engeli, A.-C. Lehmann, J. Kaminski et al., “Influence of dietary fat intake on the endocannabinoid system in lean and obese subjects,” Obesity, vol. 22, no. 5, pp. E70–E76, 2014. View at Publisher · View at Google Scholar · View at Scopus
  44. D. A. de Luis, H. F. Ovalle, G. D. Soto, O. Izaola, B. de la Fuente, and E. Romero, “Role of genetic variation in the cannabinoid receptor gene (CNR1) (G1359A Polymorphism) on weight loss and cardiovascular risk factors after liraglutide treatment in obese patients with diabetes mellitus type 2,” Journal of Investigative Medicine, vol. 62, no. 2, pp. 324–327, 2014. View at Publisher · View at Google Scholar · View at Scopus
  45. D. A. de Luis, R. Aller, M. G. Sagrado, R. Conde, O. Izaola, and B. de la Fuente, “Genetic variation in the cannabinoid receptor gene (CNR1) (G1359A polymorphism) and their influence on anthropometric parameters and metabolic parameters under a high monounsaturated vs. high polyunsaturated fat hypocaloric diets,” Journal of Nutritional Biochemistry, vol. 24, no. 8, pp. 1431–1435, 2013. View at Publisher · View at Google Scholar · View at Scopus
  46. M. Tsoli, A. Chronaiou, I. Kehagias, F. Kalfarentzos, and T. K. Alexandrides, “Hormone changes and diabetes resolution after biliopancreatic diversion and laparoscopic sleeve gastrectomy: a comparative prospective study,” Surgery for Obesity and Related Diseases, vol. 9, no. 5, pp. 667–677, 2013. View at Publisher · View at Google Scholar · View at Scopus
  47. D. Bradley, C. Conte, B. Mittendorfer et al., “Gastric bypass and banding equally improve insulin sensitivity and beta cell function,” The Journal of Clinical Investigation, vol. 122, no. 12, pp. 4667–4674, 2012. View at Publisher · View at Google Scholar · View at Scopus
  48. C. Mason, L. Xiao, I. Imayama et al., “The effects of separate and combined dietary weight loss and exercise on fasting ghrelin concentrations in overweight and obese women: a randomized controlled trial,” Clinical Endocrinology, vol. 82, no. 3, pp. 369–376, 2015. View at Publisher · View at Google Scholar
  49. D. Osei-Hyiaman, J. Liu, L. Zhou et al., “Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice,” The Journal of Clinical Investigation, vol. 118, no. 9, pp. 3160–3169, 2008. View at Publisher · View at Google Scholar · View at Scopus